Walleye Capital
MRNA icon

Walleye Capital’s Moderna MRNA Stock Holding History

Walleye Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.7K Buy
781
+610
+357% +$31.6K ﹤0.01% 4153
2026
Q1 		$8.69K Sell
171
-171,988
-100% -$8.02M ﹤0.01% 4168
2025
Q4 		$5.08M Buy
172,159
+22,648
+15% +$615K 0.02% 1140
2025
Q3 		$3.86M Buy
149,511
+123,592
+477% +$3.45M 0.01% 1095
2025
Q2 		$715K Sell
25,919
-284,304
-92% -$7.49M ﹤0.01% 2327
2025
Q1 		$8.79M Buy
310,223
+234,872
+312% +$8.33M 0.04% 496
2024
Q4 		$3.13M Buy
75,351
+47,120
+167% +$2.25M 0.01% 1394
2024
Q3 		$1.89M Buy
28,231
+9,616
+52% +$883K ﹤0.01% 2008
2024
Q2 		$2.21M Buy
18,615
+10,223
+122% +$1.29M ﹤0.01% 2010
2024
Q1 		$894K Buy
+8,392
New +$846K ﹤0.01% 2698
2021
Q3 		– Sell
-3,232
Closed -$759K – 1734
2021
Q2 		$759K Buy
+3,232
New +$578K 0.03% 562
2020
Q1 		– Sell
-1,187
Closed -$27.3K – 1399
2019
Q4 		$23K Sell
1,187
-13,313
-92% -$236K ﹤0.01% 1595
2019
Q3 		$231K Sell
14,500
-2,100
-13% -$31K 0.01% 1131
2019
Q2 		$243K Buy
+16,600
New +$357K 0.03% 861

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Walleye Capital's MRNA Position: Q2 2026 in Review

Walleye Capital increased its Moderna (MRNA) stake by 357% in Q2 2026, buying an estimated $31.6K and bringing the position to 781 shares worth $54.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4153.

Walleye Capital first reported a position in MRNA in Q2 2019 and has held it in 14 quarters since. The position peaked at $8.79M in Q1 2025. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Walleye Capital held 781 shares of Moderna worth $54.7K as of Q2 2026.
  • Walleye Capital bought 610 Moderna shares in Q2 2026, an estimated $31.6K.
  • Moderna made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4153 holding.
  • Walleye Capital first reported a position in Moderna in Q2 2019 and has held it in 14 quarters since.
  • Walleye Capital's Moderna position peaked at $8.79M in Q1 2025.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.